141 related articles for article (PubMed ID: 36698317)
1. Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.
Boglione-Kerrien C; Morcet J; Scailteux LM; Bénézit F; Camus C; Mear JB; Gangneux JP; Bellissant E; Tron C; Verdier MC; Lemaitre F
Mycoses; 2023 May; 66(5):396-404. PubMed ID: 36698317
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring.
Eiden C; Cociglio M; Hillaire-Buys D; Eymard-Duvernay S; Ceballos P; Fegueux N; Peyrière H
Xenobiotica; 2010 Oct; 40(10):701-6. PubMed ID: 20642349
[TBL] [Abstract][Full Text] [Related]
3. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
[TBL] [Abstract][Full Text] [Related]
4. Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide.
Schulz J; Michelet R; Zeitlinger M; Mikus G; Kloft C
Pharm Res; 2022 Nov; 39(11):2991-3003. PubMed ID: 36171344
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
6. A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications.
Schulz J; Michelet R; Joseph JF; Zeitlinger M; Schumacher F; Mikus G; Kloft C
J Pharm Biomed Anal; 2022 Feb; 210():114551. PubMed ID: 34999435
[TBL] [Abstract][Full Text] [Related]
7. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
[TBL] [Abstract][Full Text] [Related]
9. Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans.
Schulz J; Michelet R; Zeitlinger M; Mikus G; Kloft C
Pharm Res; 2022 Dec; 39(12):3279-3291. PubMed ID: 36271205
[TBL] [Abstract][Full Text] [Related]
10. Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma.
Xiong X; Zhai S; Duan J
Clin Chem Lab Med; 2013 Feb; 51(2):339-46. PubMed ID: 23095205
[TBL] [Abstract][Full Text] [Related]
11. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
12. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis.
Butler-Laporte G; Langevin MC; Lemieux C; Poirier C; Ferraro P; Théorêt Y; Luong ML
Clin Transplant; 2022 Aug; 36(8):e14709. PubMed ID: 35575963
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
Wang X; Zhao J; Wen T; Liao X; Luo B
Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
[TBL] [Abstract][Full Text] [Related]
18. Contribution of a Simple Bioassay in Effective Therapeutic Drug Monitoring of Posaconazole and Voriconazole.
Tonini J; Bailly S; Gautier-Veyret E; Wambergue C; Pelloux H; Thiébaut-Bertrand A; Cornet M; Stanke-Labesque F; Maubon D
Ther Drug Monit; 2015 Oct; 37(5):685-8. PubMed ID: 26384041
[TBL] [Abstract][Full Text] [Related]
19. Comparison of LC-MS
Ren W; Yin L; Zhang G; Zhai T; Huang J
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080374
[TBL] [Abstract][Full Text] [Related]
20. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
